Welcome and Approval of 2015 Spring Meeting Minutes

8:10 - 9:10 am Trial Updates

- MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG)
  
- MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance)
  
- MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG)
  
- IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
  
- IND225 – A Phase II Study of the Assessment of Response To Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
  
- ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP)

9:10 - 10:15 am New Proposals

- Update on the Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma
  
- Management of Immunotherapy Side Effects
9:10 - 10:15 am  New Proposals Continued

- Intrallesional IL-2 plus or minus nivolumab for the treatment of intrinsic cutaneous malignant melanoma  C. Giacomantonio

- Neoadjuvant Proposal: combination of PD-1 and IDO inhibitors  X. Song

- A randomized phase II trial of Temozolomide and Cisplatin versus Nivolumab (BMS-936558) in patients with completely resected mucosal melanoma  D. Vicus

- Neoadjuvant combined immunotherapy and targeted therapy in resectable, locally advanced Stage IIIb-c and oligometastatic melanoma  C. Nessim

10:15 - 10:30 am  Break

10:30 - 11:15 am  Special Topics
(Closed - Canadian Cancer Trials Group Members Only)

- EXACTIS / CCTG Melanoma Collaboration  R. Fajzel / D. O’Donnell

11:15 - 12:00 pm  Melanoma Site Strategic Planning
(Closed - Canadian Cancer Trials Group Members Only)

- Background  J. Dancey

- Discussion  T. Petrella

12:00 pm  Meeting Adjourned

12:00 - 1:00 pm  Executive Committee meeting to follow (closed)